High-dose chemotherapy and stem cell rescue for high-risk Ewing's family of tumors

Expert Review of Anticancer Therapy

Volumn 11, Issue 2, 2011, Pages 251-262

  Rosenthal, Joseph ^a   Pawlowska, Anna B ^a  

^a City of Hope   (United States)

Author keywords

Ewing's sarcoma; hematopoietic stem cell transplant; high dose therapy

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MELPHALAN; NEOMYCIN; THIOTEPA; TREOSULFAN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ASKIN TUMOR; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; CLINICAL PROTOCOL; DOSE RESPONSE; DRUG MEGADOSE; EWING SARCOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; METASTASIS; NATURAL KILLER CELL; NECROSIS; NEUROECTODERM TUMOR; NEUROENDOCRINE TUMOR; PRIMARY TUMOR; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE TUMOR; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WHOLE BODY RADIATION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SARCOMA, EWING'S; TREATMENT OUTCOME;

EID: 79952175142     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.10.215     Document Type: Review

References (102)

1. Kinsella TJ, Miser JS, Waller B et al. Long-term follow-up of Ewing's sarcoma of bone treated with combined modality therapy. Int. J. Radiat. Oncol. Biol. Phys. 20(3), 389-395 (1991).
2. Young JL Jr, Ries LG, Silverberg E, Horm JW, Miller RW. Cancer incidence, survival, and mortality for children younger than age 15 years. Cancer 58(2 Suppl.), 598-602 (1986).
3. Sciubba DM, Okuno SH, Dekutoski MB, Gokaslan ZL. Ewing and osteogenic sarcoma: evidence for multidisciplinary management. Spine (Phila PA 1976) 34(22 Suppl.), S58-S68 (2009).
4. Roberts P, Burchill SA, Brownhill S et al. Ploidy and karyotype complexity are powerful prognostic indicators in the Ewing's sarcoma family of tumors: a study by the United Kingdom Cancer Cytogenetics and the Children's Cancer and Leukaemia Group. Genes Chromosomes Cancer 47(3), 207-220 (2008).
5. Cotterill SJ, Ahrens S, Paulussen M et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J. Clin. Oncol. 18(17), 3108-3114 (2000).
6. Paulussen M, Ahrens S, Craft AW et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J. Clin. Oncol. 16(9), 3044-3052 (1998).
7. Cangir A, Vietti TJ, Gehan EA et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 66(5), 887-893 (1990).
8. Barker LM, Pendergrass TW, Sanders JE, Hawkins DS. Survival after recurrence of Ewing's sarcoma family of tumors. J. Clin. Oncol. 23(19), 4354-4362 (2005).
9. Abudu A, Mangham DC, Reynolds GM et al. Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis. Br. J. Cancer 79(7-8), 1185-1189 (1999).
10. Ozaki T, Paulussen M, Poremba C et al. Genetic imbalances revealed by comparative genomic hybridization in Ewing tumors. Genes Chromosomes Cancer 32(2), 164-171 (2001).
11. Frei E III, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am. J. Med. 69(4), 585-594 (1980).
12. Seeger RC, Reynolds CP. Treatment of high-risk solid tumors of childhood with intensive therapy and autologous bone marrow transplantation. Pediatr. Clin. North Am. 38(2), 393-424 (1991).
13. Burdach S, Jurgens H. High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). Crit. Rev. Oncol. Hematol. 41(2), 169-189 (2002). Comprehensive review of risk-stratified treatment modalities for the Ewing's family of tumors.
14. Paulussen M, Bielack S, Jurgens H, Casali PG. Ewing's sarcoma of the bone: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl. 4), 140-142 (2009).
15. Ladenstein R, Potschger U, Le Deley MC et al. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J. Clin. Oncol. 28(20), 3284-3291 (2010). Outcome of high-dose therapy (HDT) followed by hematopoietic cell transplantation (HCT) in the largest cohort reported to date.
16. Jurgens H, Exner U, Gadner H et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 61(1), 23-32 (1988).
17. Ladenstein R, Hartmann O, Pinkerton CR. The role of megatherapy with autologous bone marrow rescue in solid tumours of childhood. Ann. Oncol. 4(Suppl. 1), 45-58 (1993).
18. Rodriguez-Galindo C, Billups CA, Kun LE et al. Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer 94(2), 561-569 (2002).
19. Shankar AG, Ashley S, Craft AW, Pinkerton CR. Outcome after relapse in an unselected cohort of children and adolescents with Ewing sarcoma. Med. Pediatr. Oncol. 40(3), 141-147 (2003).
20. Bacci G, Longhi A, Ferrari S et al. Pattern of relapse in 290 patients with nonmetastatic Ewing's sarcoma family tumors treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999. Eur. J. Surg. Oncol. 32(9), 974-979 (2006).
21. Leavey PJ, Mascarenhas L, Marina N et al. Prognostic factors for patients with Ewing sarcoma (EWS) at first recurrence following multi-modality therapy: a report from the Children's Oncology Group. Pediatr. Blood Cancer 51(3), 334-338 (2008).
22. Frohlich B, Ahrens S, Burdach S et al. [High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS]. Klin. Padiatr. 211(4), 284-290 (1999).
23. Kushner BH, Meyers PA, Gerald WL et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J. Clin. Oncol. 13(11), 2796-2804 (1995).
24. Dunst J, Paulussen M, Jurgens H. Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies. Strahlenther. Onkol. 169(10), 621-623 (1993).
25. Paulussen M, Braun-Munzinger G, Burdach S et al. [Results of treatment of primary exclusively pulmonary metastatic Ewing sarcoma. A retrospective analysis of 41 patients]. Klin. Padiatr. 205(4), 210-216 (1993).
26. Wessalowski R, Jurgens H, Bodenstein H et al. [Results of treatment of primary metastatic Ewing sarcoma. A retrospective analysis of 48 patients]. Klin. Padiatr. 200(3), 253-260 (1988).
27. Paulussen M, Ahrens S, Burdach S et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann. Oncol. 9(3), 275-281 (1998).
28. Burdach S, Jurgens H, Peters C et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J. Clin. Oncol. 11(8), 1482-1488 (1993).
29. Meyers PA, Krailo MD, Ladanyi M et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J. Clin. Oncol. 19(11), 2812-2820 (2001).
30. Burdach S, Thiel U, Schoniger M et al. Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases. Bone Marrow Transplant. 45(3), 483-489 (2010). Discusses the potential use of intensity modulated radiation therapy (IMRT) techniques as part of HDT prior to HCT.
31. Picci P, Rougraff BT, Bacci G et al. Prognostic significance of histopathologic response to chemotherapy in nonmetastatic Ewing's sarcoma of the extremities. J. Clin. Oncol. 11(9), 1763-1769 (1993).
32. Bacci G, Ferrari S, Bertoni F et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J. Clin. Oncol. 18(1), 4-11 (2000).
33. McLean TW, Hertel C, Young ML et al. Late events in pediatric patients with Ewing sarcoma/primitive neuroectodermal tumor of bone: the Dana-Farber Cancer Institute/Children's Hospital experience. J. Pediatr. Hematol. Oncol. 21(6), 486-493 (1999).
34. Craft AW, Cotterill SJ, Bullimore JA, Pearson D. Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur. J. Cancer 33(7), 1061-1069 (1997).
35. Fizazi K, Dohollou N, Blay JY et al. Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J. Clin. Oncol. 16(12), 3736-3743 (1998).
36. Sandoval C, Meyer WH, Parham DM et al. Outcome in 43 children presenting with metastatic Ewing sarcoma: the St. Jude Children's Research Hospital experience, 1962 to 1992. Med. Pediatr. Oncol. 26(3), 180-185 (1996).
37. Ahrens S, Hoffmann C, Jabar S et al. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma study. Med. Pediatr. Oncol. 32(3), 186-195 (1999).
38. Jurgens H, Gobel V, Michaelis J et al. [The Cooperative Ewing Sarcoma study CESS 81 of the German Pediatric Oncology Society - analysis after 4 years]. Klin. Padiatr. 197(3), 225-232 (1985).
39. Gobel V, Jurgens H, Etspuler G et al. Prognostic significance of tumor volume in localized Ewing's sarcoma of bone in children and adolescents. J. Cancer Res. Clin. Oncol. 113(2), 187-191 (1987).
40. Graham-Pole J, Lazarus HM, Herzig RH et al. High-dose melphalan therapy for the treatment of children with refractory neuroblastoma and Ewing's sarcoma. Am. J. Pediatr. Hematol. Oncol. 6(1), 17-26 (1984).
41. Lazarus HM, Herzig RH, Graham-Pole J et al. Intensive melphalan chemotherapy and cryopreserved autologous bone marrow transplantation for the treatment of refractory cancer. J. Clin. Oncol. 1(6), 359-367 (1983).
42. Cornbleet MA, Corringham RE, Prentice HG, Boesen EM, McElwain TJ. Treatment of Ewing's sarcoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Treat. Rep. 65(3-4), 241-244 (1981).
43. Pritchard J, McElwain TJ, Graham-Pole J. High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma. Br. J. Cancer 45(1), 86-94 (1982).
44. Hartmann O, Kalifa C, Benhamou E et al. Treatment of advanced neuroblastoma with high-dose melphalan and autologous bone marrow transplantation. Cancer Chemother. Pharmacol. 16(2), 165-169 (1986).
45. Burdach S, Jurgens H, Peters C et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J. Clin. Oncol. 11(8), 1482-1488 (1993).
46. Chard RL Jr, Krivit W, Bleyer WA, Hammond D. Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report. Cancer Treat. Rep. 63(11-12), 1755-1759 (1979).
47. Lucidarme N, Valteau-Couanet D, Oberlin O et al. Phase II study of high-dose thiotepa and hematopoietic stem cell transplantation in children with solid tumors. Bone Marrow Transplant. 22(6), 535-540 (1998).
48. Hartmann O, Oberlin O, Beaujean F et al. [Role of high-dose chemotherapy followed by bone marrow autograft in the treatment of metastatic Ewing's sarcoma in children]. Bull. Cancer 77(2), 181-187 (1990).
49. Chan LL, Ater J, Cangir A et al. Fractionated high-dose cyclophosphamide for advanced pediatric solid tumors. J. Pediatr. Hematol. Oncol. 18(1), 63-67 (1996).
50. Saeter G, Alvegard TA, Elomaa I et al. Chemotherapy for osteosarcoma and Ewing's sarcoma. Acta Orthop. Scand. Suppl. 273, 120-125 (1997).
51. Matsumoto S, Kawaguchi N, Amino K et al. [Combination chemotherapy including cis-platinum in Ewing's sarcoma]. Gan. To. Kagaku. Ryoho. 14(6 Pt 1), 1913-1916 (1987).
52. Lanvers-Kaminsky C, Bremer A, Dirksen U, Jurgens H, Boos J. Cytotoxicity of treosulfan and busulfan on pediatric tumor cell lines. Anticancer Drugs 17(6), 657-662 (2006).
53. Locatelli F, Zecca M, Messina C et al. Improvement over time in outcome for children with acute lymphoblastic leukemia in second remission given hematopoietic stem cell transplantation from unrelated donors. Leukemia 16(11), 2228-2237 (2002).
54. Oberlin O, Rey A, Desfachelles AS et al. Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Societe Francaise des Cancers de l'Enfant. J. Clin. Oncol. 24(24), 3997-4002 (2006). Long-term results of a large cohort reported by the Societe Francaise des Cancers de l'Enfant.
55. Michon J, Hartman O, Demeocq F et al. Consolidation with busulfan and melphalan following by blood progenitor cell (BPC) graft an children and young adults with high risk Ewing's Sarcoma: a report of the French Society of Pediatric Oncology (abstract). J. Clin. Oncol. 13, A1415 (1994).
56. Pession A, Rondelli R, Paolucci P et al. Hematopoietic stem cell transplantation in childhood: report from the bone marrow transplantation group of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP). Haematologica 85(6), 638-646 (2000). Results of a large cohort reported by the Associazione Italiana Ematologia Oncologia Pediatrica.
57. Ladenstein R, Lasset C, Pinkerton R et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT solid tumour registry. Bone Marrow Transplant. 15(5), 697-705 (1995).
58. Dirksen U, Lanvers-Kaminski C, Ranft A et al. Treosulfan high dose therapy with autologous stem cell rescue in high-risk Ewing tumors. J. Clin. Oncol. 25(18S), 10039 (2007).
59. Juergens H, Ranft A, Paulussen M et al. Treosulfan-based high-dose chemotherapy with autologous stem cell transplantation in high-risk Ewing sarcoma. J. Clin. Oncol. 27(15S), 10546 (2009).
60. Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93(1), 55-65 (1999).
61. Barlogie B, Jagannath S, Vesole DH et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 89(3), 789-793 (1997).
62. Fitoussi O, Simon D, Brice P et al. Tandem transplant of peripheral blood stem cells for patients with poor-prognosis Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant. 24(7), 747-755 (1999).
63. Haioun C, Mounier N, Quesnel B et al. Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: a pilot study of 36 patients. Ann. Oncol. 12(12), 1749-1755 (2001).
64. Grupp SA, Stern JW, Bunin N et al. Rapid-sequence tandem transplant for children with high-risk neuroblastoma. Med. Pediatr. Oncol. 35(6), 696-700 (2000).
65. Kletzel M, Katzenstein HM, Haut PR et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago Pilot II study. J. Clin. Oncol. 20(9), 2284-2292 (2002).
66. Burdach S, Meyer-Bahlburg A, Laws HJ et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J. Clin. Oncol. 21(16), 3072-3078 (2003).
67. Rosenthal J, Bolotin E, Shakhnovits M et al. High-dose therapy with hematopoietic stem cell rescue in patients with poor prognosis Ewing family tumors. Bone Marrow Transplant. 42(5), 311-318 (2008).
68. Jenkin RD, Rider WD, Sonley MJ. Ewing's sarcoma: adjuvant total body irradiation, cyclophosphamide and vincristine. Int. J. Radiat. Oncol. Biol. Phys. 1(5-6), 407-413 (1976).
69. Evans RG, Burgert EO, Gilchrist GS et al. Sequential half-body irradiation (SHBI) and combination chemotherapy as salvage treatment for failed Ewing's sarcoma - a pilot study. Int. J. Radiat. Oncol. Biol. Phys. 10(12), 2363-2368 (1984).
70. Nesbit ME Jr, Perez CA, Tefft M et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: an Intergroup Study. Natl Cancer Inst. Monogr. (56), 255-262 (1981).
71. Miser JS, Kinsella TJ, Triche TJ et al. Preliminary results of treatment of Ewing's sarcoma of bone in children and young adults: six months of intensive combined modality therapy without maintenance. J. Clin. Oncol. 6(3), 484-490 (1988).
72. McTiernan A, Driver D, Michelagnoli MP, Kilby AM, Whelan JS. High dose chemotherapy with bone marrow or peripheral stem cell rescue is an effective treatment option for patients with relapsed or progressive Ewing's sarcoma family of tumours. Ann. Oncol. 17(8), 1301-1305 (2006).
73. Stewart DA, Gyonyor E, Paterson AH et al. High-dose melphalan +/- total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor. Bone Marrow Transplant. 18(2), 315-318 (1996).
74. Meyers PA, Krailo MD, Ladanyi M et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J. Clin. Oncol. 19(11), 2812-2820 (2001). Demonstration of the lack of benefit in using HDT containing total-body irradiation.
75. Horowitz ME, Kinsella TJ, Wexler LH et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J. Clin. Oncol. 11(10), 1911-1918 (1993).
76. Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J. Clin. Oncol. 19(3), 870-880 (2001).
77. Hawkins D, Barnett T, Bensinger W, Gooley T, Sanders J. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-sarcoma-family tumors. Med. Pediatr. Oncol. 34(5), 328-337 (2000). The potential use of IMRT techniques as part of HDT prior to HCT.
78. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 341(8837), 85-86 (1993).
79. Rill DR, Santana VM, Roberts WM et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 84(2), 380-383 (1994).
80. Vredenburgh JJ, Silva O, Tyer C et al. A comparison of immunohistochemistry, two-color immunofluorescence, and flow cytometry with cell sorting for the detection of micrometastatic breast cancer in the bone marrow. J. Hematother. 5(1), 57-62 (1996).
81. Leung W, Chen AR, Klann RC et al. Frequent detection of tumor cells in hematopoietic grafts in neuroblastoma and Ewing's sarcoma. Bone Marrow Transplant. 22(10), 971-979 (1998).
82. Vermeulen J, Ballet S, Oberlin O et al. Incidence and prognostic value of tumour cells detected by RT-PCR in peripheral blood stem cell collections from patients with Ewing tumour. Br. J. Cancer 95(10), 1326-1333 (2006).
83. Adachi Y, Reynolds PN, Yamamoto M et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. Cancer Res. 61(21), 7882-7888 (2001).
84. Yaniv I, Stein J, Luria D et al. Ewing sarcoma tumor cells express CD34: implications for autologous stem cell transplantation. Bone Marrow Transplant. 39(10), 589-594 (2007).
85. Shimoni A, Korbling M. Tumor cell contamination in re-infused stem cell autografts: does it have clinical significance? Crit. Rev. Oncol. Hematol. 41(2), 241-250 (2002).
86. Ozaki T, Hillmann A, Hoffmann C et al. Significance of surgical margin on the prognosis of patients with Ewing's sarcoma. A report from the Cooperative Ewing's Sarcoma Study. Cancer 78(4), 892-900 (1996).
87. Rosito P, Mancini AF, Rondelli R et al. Italian Cooperative Study for the treatment of children and young adults with localized Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer 86(3), 421-428 (1999).
88. Moscovitch M, Slavin S. Anti-tumor effects of allogeneic bone marrow transplantation in (NZB X NZW)F1 hybrids with spontaneous lymphosarcoma. J. Immunol. 132(2), 997-1000 (1984).
89. Castagna L, Sarina B, Todisco E et al. Lack of activity of allogeneic stem cell transplantation with reduced-intensity conditioning regimens in advanced sarcomas. Bone Marrow Transplant. 35(4), 421-422 (2005).
90. Lucas KG, Schwartz C, Kaplan J. Allogeneic stem cell transplantation in a patient with relapsed Ewing sarcoma. Pediatr. Blood Cancer 51(1), 142-144 (2008).
91. Koscielniak E, Gross-Wieltsch U, Treuner J et al. Graft-versus-Ewing sarcoma effect and long-term remission induced by haploidentical stem-cell transplantation in a patient with relapse of metastatic disease. J. Clin. Oncol. 23(1), 242-244 (2005).
92. Burdach S, van Kaick B, Laws HJ et al. Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup study EICESS. Stem-Cell Transplant Programs at Dusseldorf University Medical Center, Germany and St. Anna Kinderspital, Vienna, Austria. Ann. Oncol. 11(11), 1451-1462 (2000).
93. Verhoeven DH, de Hooge AS, Mooiman EC et al. NK cells recognize and lyse Ewing sarcoma cells through NKG2D and DNAM-1 receptor dependent pathways. Mol. Immunol. 45(15), 3917-3925 (2008).
94. Toporski J, Garkavij M, Tennvall J et al. High-dose iodine-131- metaiodobenzylguanidine with haploidentical stem cell transplantation and posttransplant immunotherapy in children with relapsed/refractory neuroblastoma. Biol. Blood Marrow Transplant. 15(9), 1077-1085 (2009).
95. Lang P, Pfeiffer M, Muller I et al. Haploidentical stem cell transplantation in patients with pediatric solid tumors: preliminary results of a pilot study and analysis of graft versus tumor effects. Klin. Padiatr. 218(6), 321-326 (2006).
96. Perez-Martinez A, Lassaletta A, Gonzalez-Vicent M et al. High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. J. Neurooncol. 71(1), 33-38 (2005).
97. Prete A, Rosito P, Alvisi P et al. G-CSF-primed peripheral blood progenitor cells (PBPC) support in high-risk Ewing sarcoma of childhood. Bone Marrow Transplant. 22(Suppl. 5), S21-S23 (1998).
98. Laurence V, Pierga JY, Barthier S et al. Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor. Am. J. Clin. Oncol. 28(3), 301-309 (2005).
99. Al Faris N, Al Harbi T, Goia C et al. Does consolidation with autologous stem cell transplantation improve the outcome of children with metastatic or relapsed Ewing sarcoma? Pediatr. Blood Cancer 49(2), 190-195 (2007).
100. Burke MJ, Walterhouse DO, Jacobsohn DA, Duerst RE, Kletzel M. Tandem high-dose chemotherapy with autologous peripheral hematopoietic progenitor cell rescue as consolidation therapy for patients with high-risk Ewing family tumors. Pediatr. Blood Cancer 49(2), 196-198 (2007).
101. Czyzewski EA, Goldman S, Mundt AJ et al. Radiation therapy for consolidation of metastatic or recurrent sarcomas in children treated with intensive chemotherapy and stem cell rescue. A feasibility study. Int. J. Radiat. Oncol. Biol. Phys. 44(3), 569-577 (1999).
102. Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. National Cancer Institute: SEER Pediatric Monograph http://seer.cancer.gov/publications/ childhood/bone.pdf